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Methods: We assessed the expression patterns of CRBP-1 in 84 stage 
I non-small cell lung cancer (NSCLC), with the aim of characterizing 
their interrelationship via immunohistochemical staining (IHC) and 
survival. 
Figure 1. Expression of CRBP-1 in normal epithelial and alveolar cells
A, B, C- negative, D.focal positive. 
Figure 2. Expression of CRBP-1 in stage I non-small cell lung cancer cells, A and 
B- negative in adenoca and squamous cell ca, C and D- positive in adenoca 
and squamous cell ca. 
Results: The patients consisted of 65 men and 19 women. The mean 
age of these patients was 62 ± 10 years and 60 (71%) were smokers. 
Histologic subtypes included 40 cases of adenocarcinoma, 40 of squa-
mous cell carcinoma, and 4 of large cell carcinoma. Fourteen out of 84 
(16.7%) cases exhibited positive expression of CRBP-1 in more than 
25% of tumor cells. The sex, smoking status, tumor size, histologic 
types, and differentiation were not statistically different in the presence 
of CRBP-1 expression. In Kaplan-Meier survival analysis, expression 
of CRBP-1 proved to be a statistically signiﬁcant poor prognosis factor 
in overall survival (p=0.026). Cox regression analysis showed that the 
expression of CRBP-1 seemed to be associated with poor prognosis 
factor in stage I NSCLC (p=0.006).
Conclusions: CRBP-1 expression may play a partly role in carcino-
genesis and prognosis of early stage lung cancer. Further prospective 
studies are warranted to determine the molecular mechanism in regard 
to the role of CRBP-1 in lung carcinogenesis.
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Background: Vascular Endothelial Growth Factor (VEGF) is known to 
play an important role in angiogenic process of lung cancers. Whether 
the level of VEGF expression in cancers will reﬂect the response of 
Anti-VEGF treatment, no one know. We seek to answer two questions:
1) Can VEGF protein expression predict the lung cancer response from 
Anti-VEGF treatment? 
2)  Can Sequence Variation and Mutations of VEGF gene predict the 
tumor response In NSCLC lung cancer treatment?
Methods: Included in the study were 28 cases of NSCLC Lung can-
cers. We use Immunohistochemical (IHC) for VEGF protein expres-
sion. Their Tumor DNA were extracted and studied for polymorphism 
and mutations of VEGF gene, using DNA sequencing technique.
Results:
1) Lung NSCLC showed 70% (20/28) VEGF protein expression. With 
8 cases of strongly expressed and 12 cases of low expressed VEGF 
protein. DNA sequence of VEGF gene showed no mutations in 8 
cases of strongly expressed VEGF and 11 cases of low expressed 
VEGF protein. VEGF gene mutations occurred in VEGF negative at 
the rate of 3/8 and 1/12 in low expressed VEGF protein. The muta-
tion of VEGF gene in NSCLC lung cancer occurred at the rate of 
4/28 = 14 % 
2) Polymorphism study in all positive VEGF appeared to suggest that 
weakly expressed protein had genotype codon 108 AA with less 
tumor aggressiveness. And genotype codon 108G/G and/or codon 
108 G/A appeared to be associated with more aggressiveness.
3) All the NSCLC responders showed low expressed VEGF protein or 
VEGF negative protein
Conclusion:
1) Tumors with VEGF protein positive did not have any VEGF gene 
mutations.
2) It appeared that only VEGF protein negative tumors showed muta-
tions in their VEGF gene.
3) Low VEGF protein expression and No VEGF protein expression 
appeared to do well and survived longer after treatment. The level 
of VEGF protein expression and their relationship with EGFR and 
KRAS mutations in our NSCLC lung cancers will be included in our 
presentation. 
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Background: 14-3-3 proteins have 130 potential binding partners, 
including Cbl. 14-3-3 expression can prevent mutant EGFR binding to 
Cbl, impairing ubiquitination and endocytosis. 14-3-3 σ is frequently 
methylated in NSCLC; we hypothesized that in the presence of EGFR 
mutations, methylated 14-3-3 σ could permit the formation of the 
EGFR-Cbl complex. CHFR is a checkpoint that delays entry into meta-
phase in response to mitotic stress. 
Methods: 73 stage IV NSCLC p with EGFR exon 19 deletion or 
exon 21 L858R mutation received ﬁrst- or second-line erlotinib single 
therapy. 14-3-3σ and CHFR methylation was examined in the baseline 
serum of these p. 
Results: Median age, 63 (range, 26-83); females, 48 p (65.8%); Cauca-
sian, 72 p, Asian, 1 p; never-smokers, 45 p, ex-smokers, 21 p, smokers, 
7 p; adenocarcinoma, 64 p, large cell carcinoma, 9. PS: 0, 19 p, 1, 42 p, 
2-3, 12 p. 14-3-3σ was methylated in 39.7% and CHFR in 42.5% of p. 
No differences in p characteristics were observed according to methyla-
tion status. Complete response was observed in 11.1% of p, and partial 
response in 75.4%. Overall response was 86.5%. There was a trend 
toward a higher response rate in p with unmethylated CHFR (94.4% vs 
76.6%; P=ns). Overall median time to progression (TTP) and survival 
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(MS) have not been reached either in ﬁrst- or second-line. However, 
when split according to methylation status, there was a trend toward 
better TTP and MS in both ﬁrst- and second-line in p with methylated 
14-3-3σ. TTP in second-line in p with methylated 14-3-3σ has not been 
reached, while it was 10.8 months (m) for p with unmethylated 14-3-3σ 
(P=ns). TTP in second-line in p with methylated CHFR was 5.2 m but 
was not reached for p with unmethylated CHFR (P=0.05). 
Conclusions: Methylated 14-3-3σ can permit Cbl binding to mutant 
EGFR and predict longer-lasting response to erlotinib in p with EGFR 
mutations. The precise role of CHFR warrants further research. Com-
plete data will be presented. 
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Background: Qualitative and quantitative analysis of circulating 
DNA in blood is a promising non-invasive diagnostic and prognostic 
tool. Our aim was to study the association between the free amount 
in plasma of the catalytic subunit of telomerase (hTERT) and several 
clinical variables in advanced NSCLC patients.
Methods: We examined 451 NSCLC patients in stage IIIB and IV, 
treated with cisplatin and docetaxel. Blood samples were collected be-
fore chemotherapy, and circulating DNA was extracted from the serum 
using commercial adsorption columns. The amount of free hTERT in 
plasma was quantiﬁed by using RT-PCR.
Results: Median age was 61 years [35-82] and 84% were males. 99% 
had performance status 0-1. 84% were in stage IV and 16% in stage 
IIIB. The histological subtypes were: 32% squamous cell carcinoma, 
50% adenocarcinoma, 14% anaplastic large cell, and 4% undifferen-
tiated. 41% of the patients received second line chemotherapy. 1% 
achieved complete response (CR), 36% partial response (PR), 35% had 
stable disease (SD) and 28% progressive disease (PD). Median hTERT 
value was 4856 ng/ml; for patients in IIIB was 48 ng/ml [2-9648] and 
48 ng/ml [0.6-43735] in stage IV (p=0.75). There was not association 
between hTERT values and response to therapy. hTERT values were 
not related with the localization of the metastasis. Dividing the cohort 
in two sets according to hTERT median we found two signiﬁcantly dif-
ferent groups in terms of Overall Survival (OS) and Time To Progres-
sion (TTP). Patients with hTERT <48 ng/ml had a median TTP of 5.3 
months (m) [4.4-6.1] while for hTERT >48 ng/ml was 4.1 m [3.5-4.6], 
(p=0.0009). OS when hTERT <48 ng/ml was 10.1m [4.9-11.3] and for 
hTERT >48 ng/ml was 8.4 m [7.2-9.5], (p=0.01). In the multivariate 
analysis, hTERT was an independent predictive variable for TTP (HR 
1.39, CI 95% 1.1-1.7, p=0.002) and OS (HR 1.27, CI 95% 1.1-1.6, 
p=0.04).
Conclusions: In advanced NSCLC patients, the quantiﬁcation of free 
circulating hTERT in plasma is an affordable and valuable prognostic 
marker. High plasma hTERT levels are a poor prognostic indicator for 
TTP and OS.
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Background: EGFR has an extracellular ligand-binding domain that 
can be proteolitically cleaved from the cell surface and can be accu-
rately quantiﬁed in blood by ELISA. We have investigated the useful-
ness of plasma EGFR measurements as prognostic marker in advanced 
NSCLC.
Methods: The cohort consisted in 329 patients (p) with advanced 
NSCLC that received ﬁrst-line therapy with cisplatin and docetaxel. 
The concentration levels of the EGFR extracellular binding domain 
were determined by a sandwich quantitative ELISA in the baseline, 
before therapy.
Results: Median age was 61, range [39-80], 84% males, 100% cau-
casian, 68% stage IIIB and 32% IV and 99% PS 0-1. The histological 
subtypes were: 31% squamous cell carcinoma, 49% adenocarcinoma, 
15% large cell, and 5% undifferentiated. 181 p achieved complete 
response (CR), partial response (PR) or stable disease (SD) and 109 
p progressive disease (PD). Median patient’s plasma levels of EGFR 
were 32.4 ng/ml. There were not differences in p according to histolo-
gy, site of metastasis and ECOG. There were differences in response to 
therapy; CR+PR+SD p presented median EGFR of 31.97 ng/ml [13.2-
48.6] vs 30 ng/ml [16.9-46.8] in the PD group (p=0.024). Dividing the 
cohort in two sets according to EGFR median we found two signiﬁ-
cantly different groups in terms of Overall Survival (OS) and Time To 
Progression (TTP). Patients with EGFR<32.4 ng/ml had a median TTP 
of 3.9 months (m) [3.3-4.6] while for EGFR>32.4 ng/ml was 4.7 m 
[4.0-5.4], (p=0.024). OS when EGFR<32.4 ng/ml was 6.9 m [5.9-7.8] 
and for EGFR>32.4 ng/ml was 9.1 m [8.2-10.1], (p=0.038).
Conclusions: Patients with PD presented signiﬁcantly lower levels of 
serum EGFR than those patients with CR+PR+SD. There is a relation-
ship among lower EGFR concentration in serum with a worst prognosis 
in advanced NSCLC p in terms of TTP and OS.
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Background: Qualitative analysis of circulating DNA in blood is a 
promising non-invasive diagnostic and prognostic tool. Our aim was to 
